Erasca priced an upsized public offering of 22.5 million shares at $10.00 per share to raise approximately $225 million, with an underwriter option for another 3.375 million shares. The financing aims to support the clinical‑stage oncology company’s RAS/MAPK pathway programs and general corporate needs. A separate Form 8‑K showed Erasca had filed a proposed $150 million offering the day prior, underscoring urgent capital needs among precision oncology developers amid active clinical programs. Erasca said the offering is expected to close Jan. 23, subject to customary conditions. The transactions illustrate how clinical‑stage biotechs are using public markets to fund multiple trials concurrently; pipeline progress and near‑term readouts will determine the company’s burn profile and longer‑term funding strategy. Sources: Erasca press releases and SEC filing summaries.